Skip to main content

Advertisement

Table 1 Descriptive characteristics of examined cohorts

From: Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases

Gender n (%)
 F 15/30 (50 %)
 M 15/30 (50 %)
Age, median (IQR) 33 (29; 44)
Diagnosis n (%)
 CD 18/30 (60 %)
  L1 8/18 (44 %)
  L2 2/18 (12 %)
  L3 8/18 (44 %)
  B1 6/18 (33 %)
  B2 7/18 (39 %)
  B2 + 3 4/18 (22 %)
  B3 1/18 (6 %)
 UC 12/30 (40 %)
  E2 4/12 (33 %)
  E3 8/12 (67 %)
Concomitant treatment n (%)
 Immunosuppressants 11/30 (37 %)
 Corticosteroids 16/30 (53 %)
 Mesalazine 21/30 (70 %)
Response to the IFX treatment n (%)
 Responders 20/30 (67 %)
 Responders with adverse events 6/30 (20 %)
 Primary non-responders 1/30 (3 %)
 Secondary non-responders 3/30 (10 %)
  1. F females, M males, IQR interquartile range, IFX infliximab, CD Crohn’s disease, L1 ileal location of CD, L2 colonic location of CD, L3 ileo-colonic location of CD, B1 non-stricturing non-penetrating behavior of CD, B2 stricturing behavior of CD, B3 penetrating behavior of CD [16], UC ulcerative colitis, E2 left-sided UC, E3 extensive UC [16]